Inchcape Group CFO Gijsbert De Zoeten Resigns; Adrian Lewis Named Acting Group CFO

Inchcape Plc (INCH.L), an automotive distributor, announced Monday that Group Chief Financial Officer Gijsbert de Zoeten has voluntarily tendered his resignation. He will be standing down from the Board with immediate effect.

The company has appointed Adrian Lewis, currently Group Financial Controller, as Acting Group Chief Financial Officer. Lewis joined Inchcape in 2015, initially as CFO for the Emerging Markets region.

A process to identify a permanent successor is being initiated.

Inchcape noted that Gijsbert de Zoeten's resignation follows a recent incident during an event, where, through a lapse in judgement, he displayed personal behaviour falling short of the high standards expected of the leadership of the Group.

Meanwhile, the latest decision is unrelated to the company's financial performance or strategic direction, including the Derco acquisition.

The company expects to publish the Class 1 Circular to shareholders later today, and will reaffirm the Group's 2022 outlook and the expected timetable to completion of the Derco transaction.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT